Policy

For certain non-exempt studies, the IRB may approve a consent procedure that alters or excludes some or all of the elements of informed consent, or may waive the requirement to document consent (obtain a signed consent form) for some or all participants. For situations in which documentation of informed consent is waived, the IRB may still require the researcher to provide participants with a written information statement regarding the research. The IRB must document its justification for any waiver or alteration to the standard requirements for informed consent.

Procedures

1. Approval of Waivers

   a. Any waivers of documentation or alterations to informed consent must be voted on separately from the vote for approval of the protocol for both expedited and full-board protocols under review. For protocols being reviewed under expedited review procedures, all reviewers, as well as the Chair reviewing the protocol, must vote to approve the waiver. For protocols being reviewed under full board review, the IRB must approve the waiver by majority vote.

   b. For FDA-regulated research, the IRB may determine that a waiver or alteration of informed consent is permissible for clinical investigations involving no more than minimal risk to participants, consistent with the FDA guidance on this topic published July 2017.
2. Use of Deception

a. When deception is a necessary and integral part of a study design, preliminary consent must still be obtained whereby the researcher informs the participant about the research. Deception generally requires that after the research interventions have been completed, the researcher explains the nature of and need for the deception to the participants and then seeks their post-facto approval of the deception. The participant’s acceptance or refusal of the explanation provided should be recorded in the researcher’s notes, but does not require a signature of the participant.

b. If an individual participant refuses to accept the explanation provided and requests that any information collected from or about him or her be destroyed, the researcher should comply with this request to the extent feasible.

c. If a preponderance of participants do not accept the explanation offered of the need for deception, even if they are willing to continue to participate in the research, a report of an unexpected problem in the research must be reported to the IRB. Any other unexpected problems that arise from the use of deception also must be reported to the IRB in a timely manner. Debriefing participants of the use of deception may be done after each individual participant or after the entire group of participants have completed the research procedures, depending on the study design.

Guidance

1. Exclusions of or Alterations to Elements of Informed Consent:
   a. General waiver or alteration of consent

HHS regulations at 45 CFR 46.116(f) and FDA guidance on waiving informed consent published July 2017 require that the IRB make and document rationale for approving a consent procedure which does not include, or which alters, some or all of the required elements of informed consent or when waiving the requirement to obtain informed consent. For expedited reviews, these findings can be documented by the designated reviewers or IRB Chairperson. For research reviewed by the convened IRB, these findings must be documented in the meeting minutes. The required findings are:

   i. The research involves no more than minimal risk to the subjects;
   ii. The waiver or alteration will not adversely affect the rights and welfare of the subjects;
   iii. The research could not practicably be carried out without the requested waiver or alteration;
   iv. Whenever appropriate, the subjects or legally authorized representatives will be provided with additional pertinent information after participation; and
v. For studies reviewed under HHS regulations, if the research involves using identifiable private information or identifiable biospecimens, the research could not practicably be carried out without using such information or biospecimens in an identifiable format. (Note: The FDA does not require documentation of this particular finding.)

b. Research involving public benefit and service programs conducted by or subject to the approval of state or local officials.

i. In order for an IRB to waive or alter consent as described in this subsection (45 CFR 46.116(e)), the IRB must find and document that:
   a. The research or demonstration project is to be conducted by or subject to the approval of state or local government officials and is designed to study, evaluate, or otherwise examine:
      i. Public benefit or service programs;
      ii. Procedures for obtaining benefits or services under those programs;
      iii. Possible changes in or alternatives to those programs or procedures; or
      iv. Possible changes in methods or levels of payment for benefits or services under those programs; and
   b. The research could not practicably be carried out without the waiver or alteration.

ii. The Investigator must provide the IRB with written documentation from an appropriate government official indicating the project is endorsed by the state or local government agency, and the project meets one of the above criteria.

2. Waiver of Documentation of Informed Consent:

An IRB may waive the requirement for the investigator to obtain a signed informed consent form for some or all subjects if it finds any of the following (45 CFR 46.117(c); 21 CFR 56.109(c)):

a. That the only record linking the subject and the research would be the informed consent form and the principal risk would be potential harm resulting from a breach of confidentiality. Each subject (or legally authorized representative) will be asked whether the subject wants documentation linking the subject with the research, and the subject's wishes will govern;

b. That the research presents no more than minimal risk of harm to subjects and involves no procedures for which written consent is normally required outside of the research context; or
c. If the subjects or legally authorized representatives are members of a district cultural group or community in which signing forms is not the norm, that the research presents no more than minimal risk of harm to subjects and provided there is an appropriate alternative mechanism for documenting that informed consent was obtained.

3. Waiver of parental permission and 45 CFR 46.408(c) and (e) Requirements for permission by parents or guardians for assent by children

a. 45 CFR 46.408(c): The IRB may waive the requirements for obtaining parental or guardian permission if either of the following 2 conditions is met:

i. The IRB makes and documents the required findings under either 45 CFR 46.116(e) or (f) [the “practicability conditions”], OR

ii. The IRB determines that a research protocol is designed to study conditions in children or a subject population for which parental or guardian permission is not a reasonable requirement to protect the subjects (for example, neglected or abused children) AND the following two additional criteria are also met:

   a. An appropriate mechanism is in place to protect the children, AND

   b. The waiver is not inconsistent with federal, state or local law.

The choice of an appropriate substitute mechanism (for example, appointing a child advocate or assent monitor) for protecting children participating in research would depend on the nature and purpose of the activities described in the protocol, the risk and anticipated benefit to the research subjects, and the child’s age, maturity, status, and condition.

Note that the IRB may waive the requirement for obtaining parental or guardian permission under 45 CFR 46.408(c) even if the research involves more than minimal risk to the child subjects.

b. 45 CFR 46.408(e): When the IRB determines that assent is required, it shall also determine whether and how assent must be documented